ACT-EARLY OLE - Clinical Trial
What is the Purpose of this Study?
People in the study will have visits every 6 months for up to 5 years. At these visits, doctors will take blood and urine samples. At some visits, they will do a heart test called an echocardiogram and ask questions about how the person feels and their quality of life. At each visit, participants will get a medicine called Acoramidis to take two times every day.
Newly diagnosed Cardiac Amyloidosis
Who Can Participate in the Study?
To join this study, you must have finished the ACT-EARLY study in the last 60 days and have a heart problem called ATTR-CM. You cannot join if you already have a nerve problem called ATTR-PN, if you have a different type of amyloid disease, or if you have very serious kidney disease (stage IV or V).
What is Involved?
This study is testing a medicine called Acoramidis to see if it helps people with a heart problem called ATTR-CM. Some people also have another problem called ATTR-PN, which affects the nerves. The study will include people who were in an earlier study and were recently told they have ATTR-CM or both ATTR-CM and ATTR-PN. If someone has both problems, they can join this study for their heart, and their nerve problem will be treated by their doctor outside the study. If someone gets ATTR-PN later, they can stay in the study for their heart and still get care for their nerves outside the study.
Study Details
